NASDAQ:COGT Cogent Biosciences (COGT) Stock Price, News & Analysis $9.52 +0.30 (+3.25%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.21▼$9.5650-Day Range$7.29▼$9.5252-Week Range$3.67▼$13.36Volume417,600 shsAverage Volume1.66 million shsMarket Capitalization$910.21 millionP/E RatioN/ADividend YieldN/APrice Target$14.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cogent Biosciences alerts: Email Address Cogent Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside54.1% Upside$14.67 Price TargetShort InterestBearish10.87% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.19) to ($2.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.06 out of 5 starsMedical Sector820th out of 936 stocksPharmaceutical Preparations Industry382nd out of 436 stocks 3.4 Analyst's Opinion Consensus RatingCogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCogent Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Cogent Biosciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.87% of the outstanding shares of Cogent Biosciences have been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Cogent Biosciences has recently increased by 7.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCogent Biosciences does not currently pay a dividend.Dividend GrowthCogent Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COGT. Previous Next 2.4 News and Social Media Coverage News SentimentCogent Biosciences has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cogent Biosciences this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cogent Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.92% of the stock of Cogent Biosciences is held by insiders.Read more about Cogent Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cogent Biosciences are expected to grow in the coming year, from ($2.19) to ($2.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cogent Biosciences is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cogent Biosciences is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCogent Biosciences has a P/B Ratio of 4.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cogent Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Cogent Biosciences Stock (NASDAQ:COGT)Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More COGT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COGT Stock News HeadlinesJuly 26 at 1:30 AM | americanbankingnews.comCogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.67 Average Target Price from BrokeragesJuly 16, 2024 | americanbankingnews.comContrasting Cogent Biosciences (NASDAQ:COGT) & Arvinas (NASDAQ:ARVN)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 23, 2024 | seekingalpha.comCogent Biosciences: Inflection Year Directly AheadJune 14, 2024 | globenewswire.comCogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)May 23, 2024 | globenewswire.comCogent Biosciences Appoints Cole Pinnow as Chief Commercial OfficerMay 23, 2024 | globenewswire.comCogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual MeetingMay 17, 2024 | investing.comCogent Biosciences Inc (COGT)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 13, 2024 | finance.yahoo.comWe Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business GrowthMay 8, 2024 | markets.businessinsider.comBuy Rating on Cogent Biosciences Backed by Strong Financials and Promising Drug TrialsMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Cogent Biosciences (COGT) and Adaptive Biotechnologies (ADPT)May 7, 2024 | markets.businessinsider.comBuy Recommendation for Cogent Biosciences Based on Promising Clinical Trials and Market PositionMay 7, 2024 | finance.yahoo.comCogent Biosciences Reports First Quarter 2024 Financial ResultsApril 18, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)April 9, 2024 | globenewswire.comCogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 InhibitorMarch 16, 2024 | finance.yahoo.comCOGT Apr 2024 7.500 callMarch 14, 2024 | insidermonkey.com5 Best Biotech Stocks To Buy Under $20See More Headlines Receive COGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COGT CUSIPN/A CIK1460329 Webwww.cogint.com Phone(617) 945-5576FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$14.67 High Stock Price Target$20.00 Low Stock Price Target$8.00 Potential Upside/Downside+58.9%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-91.56% Return on Assets-55.20% Debt Debt-to-Equity RatioN/A Current Ratio12.05 Quick Ratio12.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book4.01Miscellaneous Outstanding Shares95,610,000Free Float89,953,000Market Cap$882.48 million OptionableOptionable Beta1.71 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Andrew R. Robbins M.B.A. (Age 48)President, CEO & Director Comp: $1.06MDr. John Edward Robinson Ph.D. (Age 49)Chief Scientific Officer Comp: $749.89kDr. Jessica Sachs M.D. (Age 49)Chief Medical Officer Comp: $773.92kMr. John L. Green C.A. (Age 44)CPA, CFO & Principal Accounting Officer Comp: $763.99kMr. Brad BarnettChief Technology OfficerChristi WaarichSenior Director of Investor RelationsMr. Evan D. Kearns J.D. (Age 44)Chief Legal Officer & Corporate Secretary Ms. Erin SchellhammerChief People OfficerMr. Dana R. Martin Pharm.D.Senior VP of Medical Affairs & Chief Patient OfficerBrad FellSenior Vice President of ChemistryMore ExecutivesKey CompetitorsImmunomeNASDAQ:IMNMAytu BioPharmaNASDAQ:AYTUArcellxNASDAQ:ACLXXenon PharmaceuticalsNASDAQ:XENEMerusNASDAQ:MRUSView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 45,770 shares on 7/26/2024Ownership: 0.342%Hennion & Walsh Asset Management Inc.Bought 127,712 shares on 7/20/2024Ownership: 0.134%Farallon Capital Management LLCBought 445,000 shares on 5/24/2024Ownership: 0.483%Kennedy Capital Management LLCBought 385,315 shares on 5/16/2024Ownership: 0.738%California State Teachers Retirement SystemBought 8,804 shares on 5/16/2024Ownership: 0.067%View All Institutional Transactions COGT Stock Analysis - Frequently Asked Questions How have COGT shares performed this year? Cogent Biosciences' stock was trading at $5.88 at the beginning of 2024. Since then, COGT stock has increased by 61.9% and is now trading at $9.52. View the best growth stocks for 2024 here. How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:COGT) posted its quarterly earnings data on Tuesday, May, 7th. The technology company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.11. Who are Cogent Biosciences' major shareholders? Cogent Biosciences' top institutional shareholders include Bank of New York Mellon Corp (0.34%) and Hennion & Walsh Asset Management Inc. (0.13%). View institutional ownership trends. How do I buy shares of Cogent Biosciences? Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ) and Nutanix (NTNX). This page (NASDAQ:COGT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.